x

75% of people globally want unbiased news (Pew Research) but are concerned they're not getting that.

Get balanced coverage with Symby. See how stories are covered across diverse outlets and spot when one side covers a story the other skips.

PODCAST

Oncology On The Go

Oncology On The Go is a weekly podcast that talks to authors and experts to thoroughly examine featured articles in the journal ONCOLOGY and review other challenging treatment scenarios in the cancer field from a multidisciplinary perspective. Our discussions also offer timely insight into topics ranging from recent FDA approvals to relevant research presented at major oncology conferences. As the home of the journal ONCOLOGY, CancerNetwork offers different perspectives on oncology/hematology

science medicine

All Episodes

10:20

S1 Ep45: Real-World Assessment of Care and Efficiency...

Oncology On The Go ·

2022/03/28

This week, CancerNetwork spoke with Matthew Matasar, MD, a lymphoma specialist and chief of the Medical Oncology Service at Memorial Sloan Kettering Cancer Center Bergen, about research from the December issue of ONCOLOGY titled, “Real-World Assessment of Patient Care and Practice Efficiency With the Introduction of Subcutaneous Rituximab.” The retrospective, observational analysis examined patient care delivery and practice efficiency changes using real-world data. Patients with diffuse large

en-us

13:25

S1 Ep44: Neoadjuvant Chemotherapy for Elderly...

Oncology On The Go ·

2022/03/14

CancerNetwork spoke with Jun Gong, MD, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, regarding a perspective piece titled, “Cisplatin Neoadjuvant Chemotherapy in an Aging Population With Muscle-Invasive Bladder Cancer.” Gong’s perspective focuses on an article published in the January issue of ONCOLOGY titled, “Use of Neoadjuvant Chemotherapy in Elderly Patients With Muscle-Invasive Bladder Cancer: A Population-Based Study,

en-us

14:55

S1 Ep43: Ofer Sharon, MD, Discusses OncoHost and...

Oncology On The Go ·

2022/02/28

CancerNetwork® recently spoke with Ofer Sharon, MD, CEO of OncoHost, about interim results from the prospective PROPHETIC trial to predict how patients with non–small cell lung cancer respond to immunotherapy. Sharon first described OncoHost and the mission of this clinical stage precision oncology company. Then, he touched on the key details of this research, with a focus on the PROphet diagnostic platform at the center of this ongoing multicenter clinical trial, as well as what comes next for

en-us

12:54

S1 Ep42: Metastatic Basal Cell Carcinoma Arising From...

Oncology On The Go ·

2022/02/14

CancerNetwork® spoke with Emily Smith, MD, of the Ellis Fishchel Cancer Center, University of Missouri, about a patient case published in the December issue of the journal ONCOLOGY titled, “Metastatic Basal Cell Carcinoma Arising From a Primary Cutaneous Carcinosarcoma.” Smith and colleagues detailed a case regarding a 56-year-old man who the team of care providers diagnosed with metastatic basal cell carcinoma arising from a carcinosarcoma. In the conversation, Smith talked about what makes this

en-us

18:19

S1 Ep41: Matthew Allaway, DO, on Transperineal Biopsy...

Oncology On The Go ·

2022/01/31

CancerNetwork spoke with Matthew Allaway, DO, founder and CEO of Perineologic, about a new prostate cancer biopsy technique that uses the transperineal approach to detect cancer in harder to reach areas of the prostate. Allaway touched on the American Cancer Society’s annual report that shows the rate of advanced-stage prostate cancer cases are increasing in recent years. He also detailed a companion study to that report, and walked through the specific details and benefits of this biopsy

en-us

13:31

S1 Ep40: Amy Comander, MD, on SABCS and Key Breast...

Oncology On The Go ·

2022/01/17

This week, CancerNetwork closed the book on the year that was 2021. CancerNetwork spoke with Amy Comander, MD, co-medical director and director of breast oncology and cancer survivorship at Mass General Cancer Center, about some of the key developments and data to emerge from 2021 for patients with breast cancer, with a specific focus on the 2021 San Antonio Breast Cancer Symposium (SABCS). Not only did Comander detail important information from 2021 in the field of breast cancer, but she also

en-us

41:45

S2 Ep17: Between the Lines™ Podcast: Incorporating...

Oncology On The Go ·

2022/01/14

As part of its Between the Lines™ video series, CancerNetwork® spoke with Lyudmila Bazhenova, MD, a professor of medicine at the University of California San Diego Health, and Federico Albrecht, MD, an oncologist/hematologist at Miami Cancer Institute, Baptist Health South Florida, about when and how to use real-world evidence when making treatment decisions for patients with EGFR-mutated non–small cell lung cancer (NSCLC). In the video series, Bazhenova and Albrecht discussed the following: ·

en-us

26:57

S1 Ep39: Improving Experience of LGBTQ+ Patients in...

Oncology On The Go ·

2022/01/03

This week, CancerNetwork spoke with Don Dizon, MD, about certain unique challenges LGBTQ+ patients face when navigating through their cancer journey, and how providers can improve these experiences. The director of women’s cancers at the Lifespan Cancer Institute, director of medical oncology at Rhode Island Hospital, and professor of medicine at the Warren Alpert Medical School of Brown University in Providence, touched on overcoming barriers in clinical cancer research, creating a gender-affirming

en-us

7:44

S2 Ep16: Future Directions in Small Cell Lung Cancer...

Oncology On The Go ·

2021/12/22

The final episode of CancerNetwork’s 4-part series on small cell lung cancer (SCLC) welcomes back Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. In this conversation, Iams looks to the future of SCLC treatments, touching on topics including extending response durations for patients, emerging therapies for extensive stage SCLC, exciting research on the horizon, and more. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple

en-us

15:46

S1 Ep38: Relationship Between Medical Oncologists and...

Oncology On The Go ·

2021/12/20

Jun Gong, MD, discussed his perspective piece from the October issue of the journal ONCOLOGY, titled “An Evolving Relationship Between Medical Oncologists and Genetic Counselors in Prostate Cancer.” Gong, a practicing medical oncologist who specializes in the treatment of genitourinary cancers at Cedars-Sinai Medical Center, commented on a review article previously examined on this podcast with Alexandra Sokolova, MD, titled “Germline Testing in Prostate Cancer: When and Who to Test.” The review

en-us

13:21

S2 Ep15: Practical Considerations for Small Cell Lung...

Oncology On The Go ·

2021/12/16

In the third part of a 4-part series on small cell lung cancer (SCLC), CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. The conversation focused on the toxicities of treatment options, quality of life for patients, and how Iams suggests managing and mitigating those events for individuals with SCLC. Some of the agents and regimens discussed include lurbinectedin and trilaciclib, as well as chemotherapy and immunotherapy. Don’t forget

en-us

20:05

S1 Ep37: Increasing Testing Access and Guiding...

Oncology On The Go ·

2021/12/06

This week’s conversation focuses on TrialJectory, a digital health company that utilizes artificial intelligence to inform patients with cancer on their treatment journey. CancerNetwork spoke with Tzvia Bader, CEO and co-founder of TrialJectory, and Karine Perreault, who recently was diagnosed with breast cancer and is on the TrialJectory platform. The conversation touches on the perceived disconnect between the pharmaceutical industry and patients, the need to remove barriers to access testing,

en-us

13:38

S2 Ep14: Treatment Options for Relapsed/Refractory...

Oncology On The Go ·

2021/12/02

In the second part of a 4-part series on small cell lung cancer, CancerNetwork continued its conversation with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center. Iams turned the attention to different treatment options for patients with relapsed/refractory small cell lung cancer. Among others, Iams touched on lurbinectedin, topotecan, and some of the crucial clinical trials associated with treatment options for small cell lung cancer, including a phase 2 basket

en-us

8:30

S1 Ep36: Value of Geriatric Assessment in Patients...

Oncology On The Go ·

2021/11/22

CancerNetwork looks at research from the October issue of the journal ONCOLOGY, titled “Value of Geriatric Assessment in Patients With Genitourinary Carcinoma.” Lead author, Quirin Zangl, MD, from the Department of Neuroanesthesia, at the Christian Doppler Hospital in Salzburg, Austria, spoke in detail about the manuscript. The research featured 111 patients with urogenital carcinomas with the goal of evaluating comprehensive geriatric assessment tools to better guide these individuals. Patients

en-us

18:20

S1 Ep35: Germline Testing in Prostate Cancer: When...

Oncology On The Go ·

2021/11/08

This week, CancerNetwork looks at an article from the October issue of the journal ONCOLOGY, titled “Germline Testing in Prostate Cancer: When and Who to Test.” CancerNetwork spoke with one of the authors of this article, Alexandra Sokolova, MD, an assistant professor at Oregon Health & Science University. Sokolova detailed the article, which summarizes germline testing recommendations for prostate cancer, specifically looking at the recently updated NCCN guidelines, as well as describing care

en-us

10:08

S2 Ep13: First-Line Therapeutic Options in Small Cell...

Oncology On The Go ·

2021/11/01

In this special episode of the "Oncology Peer Review On-The-Go" podcast, CancerNetwork spoke with Wade Iams, MD, a thoracic medical oncologist at the Vanderbilt University Medical Center, about therapeutic advances for small cell lung cancer. Iams discussed the current first-line therapies for small cell lung cancer, the IMpower133 and CASPIAN trials, and the factors considered for treating patients in the first-line setting. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go"

en-us

25:10

S2 Ep12: OncView™ Podcast: Connie Batlevi, MD, PhD on...

Oncology On The Go ·

2021/10/29

As part of its OncView video series, CancerNetwork spoke with Connie Batlevi, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, about recent updates in therapies for relapsed or refractory follicular lymphoma. Batlevi discussed the current treatment options for this disease, as well as third-line therapies, tazemetostat, and sequencing changes. In the video series, Batlevi discussed the following: · Current Treatment Options and Considerations for Relapsed/Refractory

en-us

11:27

S1 Ep34: Debra Patt, MD, PhD, MBA, FASCO, on...

Oncology On The Go ·

2021/10/25

This week, CancerNetwork spoke with Debra Patt, MD, PhD, MBA, FASCO, Executive Vice President at Texas Oncology. Patt discussed the rise of telehealth during the COVID-19 pandemic, how clinicians can use these tools to help treat patients with cancer, and the role of telemedicine moving forward. Don’t forget to subscribe to the "Oncology Peer Review On-The-Go" podcast on Apple Podcasts, Spotify or anywhere podcasts are available.

en-us

36:20

S2 Ep11: Between the Lines: PET/CT-Guided...

Oncology On The Go ·

2021/10/19

As part of CancerNetwork’s Between the Lines video series, Brian Helfand, MD, PhD, Chief of the Division of Urology and the Ronald L. Chez Family and Richard Melman Family Endowed Chair at NorthShore University HealthSystem, and Steven Finkelstein, MD, FACRO, a radiation oncologist with Florida Cancer Affiliates US Oncology Network in Panama City, Florida, examined the results and clinical implications of the phase 2/3 EMPIRE-1 trial in prostate cancer. The trial compares 18F-fluciclovine PET/CT

en-us

15:41

S1 Ep33: Plasma Glutamine as a Prognostic Biomarker...

Oncology On The Go ·

2021/10/11

This episode features an examination of an article from the September issue of the journal ONCOLOGY, titled “Plasma Glutamine as a Prognostic Biomarker in Localized Prostate Cancer: Comparison of Conventional Variables in Risk Stratification.” CancerNetwork spoke with one of the authors of this research, Jun Gong, MD, a practicing medical oncologist with an emphasis in GU cancers at Cedars-Sinai Medical Center. Gong detailed PSA’s role in prostate cancer, and other potential complementary

en-us

222 results

Similar Podcasts

Classic Radio Science Fiction

solgoodmedia.com

Mission to Mars

Inception Point Ai

The 365 Days of Astronomy

365DaysOfAstronomy.org

Creek Devil

william Jevning

UFO Chronicles Podcast

Nik Hunter